
July 26, 2022
Matt Karafin, MD is a Collaborating Investigator on a Recently Awarded Multi-Institution R21 Grant From the NIH-NHBLI
The focus of the grant is to investigate red blood cell alloimmunization risk using the REDS-III databases. Red blood cell (RBC) alloimmunization is a leading cause of morbidity and mortality in transfusion and pregnancy settings, resulting in hemolytic reactions and other adverse sequelae such as hemolytic disease of the fetus and newborn. Alloimmunization occurs in …


